MX376148B - Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. - Google Patents

Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina.

Info

Publication number
MX376148B
MX376148B MX2015016995A MX2015016995A MX376148B MX 376148 B MX376148 B MX 376148B MX 2015016995 A MX2015016995 A MX 2015016995A MX 2015016995 A MX2015016995 A MX 2015016995A MX 376148 B MX376148 B MX 376148B
Authority
MX
Mexico
Prior art keywords
tamsulosin
tadalafil
compound formula
pharmaceutical capsule
active ingredients
Prior art date
Application number
MX2015016995A
Other languages
English (en)
Other versions
MX2015016995A (es
Inventor
Caleb Hyungmin Park
Jae Hyun Park
Jong Soo Woo
Yong Il Kim
Young- Su YOON
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of MX2015016995A publication Critical patent/MX2015016995A/es
Publication of MX376148B publication Critical patent/MX376148B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulga una formulación compuesta en cápsula para prevenir o tratar la disfunción eréctil y la hiperplasia prostática benigna que comprende tadalafil y tamsulosina, y un método de preparación de la misma. La formulación compuesta en cápsula de la presente invención permite la separación completa de los dos ingredientes farmacéuticamente activos y reduce al mínimo la reactividad entre los ingredientes activos, y por lo tanto proporciona una excelente estabilidad del producto al paso del tiempo, aumentando al máximo así los efectos terapéuticos de los mismos.
MX2015016995A 2013-06-28 2014-06-30 Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina. MX376148B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130076073 2013-06-28
PCT/KR2014/005813 WO2014209087A1 (en) 2013-06-28 2014-06-30 Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin

Publications (2)

Publication Number Publication Date
MX2015016995A MX2015016995A (es) 2016-04-25
MX376148B true MX376148B (es) 2025-03-07

Family

ID=52142324

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016995A MX376148B (es) 2013-06-28 2014-06-30 Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina.

Country Status (13)

Country Link
EP (1) EP3013327B1 (es)
KR (1) KR102246657B1 (es)
CN (1) CN105338970B (es)
AU (1) AU2014299447B2 (es)
BR (1) BR112015032728A2 (es)
EA (2) EA033983B1 (es)
ES (1) ES3028429T3 (es)
HK (1) HK1219889A1 (es)
MX (1) MX376148B (es)
PH (1) PH12015502721B1 (es)
RU (1) RU2672573C2 (es)
UA (1) UA118110C2 (es)
WO (1) WO2014209087A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391640B (es) * 2015-01-28 2025-03-21 Hanmi Pharmaceutical Co Ltd Capsulas compuestas que comprenden raloxifeno y vitamina d o sus derivados.
KR20160100570A (ko) * 2015-02-16 2016-08-24 한미약품 주식회사 탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제
EA201891891A1 (ru) * 2016-03-31 2019-04-30 Ханми Фарм. Ко., Лтд. Комбинированный препарат в виде капсулы, содержащий тадалафил и тамсулозин и обладающий улучшенной стабильностью и скоростью растворения
WO2017171483A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 타다라필 및 암로디핀 함유 고형 복합제제
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
KR102169926B1 (ko) * 2018-01-12 2020-10-26 주식회사 종근당 탐스로신과 타다라필을 포함하는 약제학적 조성물
KR102805424B1 (ko) 2019-12-23 2025-05-13 한미약품 주식회사 탐수로신 및 타다라필을 포함하는 경구용 복합제제 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100221321A1 (en) * 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
KR100706036B1 (ko) 2005-04-04 2007-04-11 대화제약 주식회사 염산 탐술로신 서방성 정제 및 그의 간단한 제조방법
DE102005016981A1 (de) * 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
KR100795419B1 (ko) * 2006-01-03 2008-01-17 (주)네오메딕스 암로디핀 및 아스피린을 함유하는 약학 제제
EP2106792A1 (en) * 2008-04-02 2009-10-07 Pelvipharm Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형

Also Published As

Publication number Publication date
PH12015502721A1 (en) 2016-03-14
KR102246657B1 (ko) 2021-04-30
EP3013327A1 (en) 2016-05-04
MX2015016995A (es) 2016-04-25
RU2016102605A3 (es) 2018-05-15
RU2672573C2 (ru) 2018-11-16
WO2014209087A1 (en) 2014-12-31
AU2014299447A1 (en) 2015-12-17
EP3013327B1 (en) 2025-05-14
ES3028429T3 (en) 2025-06-19
EA201690100A1 (ru) 2016-04-29
EA201992020A1 (ru) 2020-01-16
CN105338970A (zh) 2016-02-17
KR20150002550A (ko) 2015-01-07
RU2016102605A (ru) 2017-08-02
EA033983B1 (ru) 2019-12-17
EP3013327A4 (en) 2016-11-16
CN105338970B (zh) 2019-07-09
BR112015032728A2 (pt) 2017-07-25
PH12015502721B1 (en) 2016-03-14
HK1219889A1 (zh) 2017-04-21
AU2014299447B2 (en) 2019-01-17
EA039091B1 (ru) 2021-12-02
UA118110C2 (uk) 2018-11-26

Similar Documents

Publication Publication Date Title
MX376148B (es) Formulacion compuesta en capsula farmaceutica que comprende tadalafil y tamsulosina.
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
ZA201902053B (en) Pharmaceutical composition
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2017000026A (es) Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
MX378435B (es) Administración específica del sitio de un inhibidor de btk.
HK1251481A1 (zh) 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
MX2017003561A (es) Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos.
IN2014MU00303A (es)
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
CR20160527A (es) Derivados de carboxamida
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MY194081A (en) Physiologically balanced injectable formulations of fosnetupitant
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
PH12020500510A1 (en) Prophylactic and/or therapeutic agent for diseases involving ido expression
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
MX2021016053A (es) Formulaciones de espuma rectal.
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
EA201691763A1 (ru) Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted